Drug
Tucatinib
Tucatinib: highest development phase Phase 3, developed by Biocon, Pfizer, Seagen and others. 10 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Biocon, Pfizer, Seagen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tucatinib NCT05132582 | Phase 3 | HER2 Positive Breast Cancer |
| tucatinib NCT05253651 | Phase 3 | Colorectal Neoplasms |
| tucatinib NCT03975647 | Phase 3 | HER2-positive Breast Cancer |
| Tucatinib 150 MG NCT06016387 | Phase 2 | HER2-positive Breast Cancer |
| tucatinib NCT04579380 | Phase 2 | Uterine Neoplasms |
| Tucatinib NCT04896320 | Phase 1/2 | Breast Cancer Stage IV |
| tucatinib NCT03758339 | Phase 1 | Healthy |
| Tucatinib (ONT-380) NCT01983501 | Phase 1 | HER2 Positive Breast Cancers |
| tucatinib NCT03777761 | Phase 1 | Healthy |
| Tucatinib NCT03826602 | Phase 1 | Drug-drug Interaction |
Latest
No recent events.
Follow Tucatinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.